Table 1.
Clinical and demographic characteristics of participants.
| Training cohort (SeekIn) |
Independent validation cohort 1 (SYSMH) |
Independent validation cohort 2 (JHUSM) |
||||
|---|---|---|---|---|---|---|
| Cancer |
Non-cancer |
Cancer |
Non-cancer |
Cancer |
Non-cancer |
|
| （n = 591） | （n = 1055） | （n = 363） | （n = 5556） | （n = 1005） | （n = 812） | |
| Platform | Roche cobas e411 | Roche cobas e601 | Bio-Rad Bioplex 200 platform | |||
| Sample type | Plasma | Serum | Plasma | |||
| Age | ||||||
| Mean（SD） | 55.3 (13.6) | 47.8 (12.4) | 58.5 (16.2) | 53.8 (17.4) | 62.9 (12.4) | 49.3 (19.5) |
| ≤55 years, n (%) | 289 (48.9%) | 788 (74.7%) | 143 (39.4%) | 2840 (51.1%) | 279 (22.8%) | 408 (50.2%) |
| ＞55 years, n (%) | 302 (51.1%) | 267 (25.3%) | 220 (60.6%) | 2716 (48.9%) | 726 (72.2%) | 404 (49.8%) |
| Sex | ||||||
| Female, n (%) | 256 (43.3%) | 543 (51.5%) | 140 (38.6%) | 2495 (44.9%) | 543 (54.0%) | 378 (46.6%) |
| Male, n (%) | 335 (56.7%) | 512 (48.5%) | 223 (61.4%) | 3061 (55.1%) | 462 (46.0%) | 434 (53.4%) |
| Cancer type | ||||||
| Lymphoma, n (%) | 159 (26.9%) | 0 (0.0%) | 0 (0.0%) | |||
| Liver, n (%) | 128 (21.7%) | 72 (19.8%) | 44 (4.4%) | |||
| Breast, n (%) | 66 (11.2%) | 16 (4.4%) | 209 (20.8%) | |||
| Colorectum, n (%) | 62 (10.5%) | 46 (12.7%) | 388 (38.6%) | |||
| Stomach, n (%) | 56 (9.5%) | 25 (6.9%) | 68 (6.8%) | |||
| Lung, n (%) | 41 (6.9%) | 155 (42.7%) | 104 (10.3%) | |||
| Pancreas, n (%) | 17 (2.9%) | 15 (4.1%) | 93 (9.3%) | |||
| Oesophagus, n (%) | 10 (1.7%) | 11 (3.0%) | 45 (4.5%) | |||
| Ovary, n (%) | 5 (0.8%) | 23 (6.3%) | 54 (5.4%) | |||
| Others, n (%) | 47 (8.0%) | 0 (0.0%) | 0 (0.0%) | |||
SYSMH, Sun Yat-sen Memorial Hospital, Sun Yat-sen University. JHUSM, Johns Hopkins University School of Medicine.